JPMorgan Health-Care Conference Attendance
This is a San Francisco news story, published by CNBC, that relates primarily to Brian Thompson news.
San Francisco news
For more San Francisco news, you can click here:
more San Francisco newsBrian Thompson news
For more Brian Thompson news, you can click here:
more Brian Thompson newsNews about health policy
For more health policy news, you can click here:
more health policy newsCNBC news
For more news from CNBC, you can click here:
more news from CNBCAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about health policy, you might also like this article about
UnitedHealthcare CEO Brian Thompson. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest care executives news, JPMorgan news, news about health policy, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
UnitedHealthcare CEOCNBC
•Health
Health
GLP-1s and Brian Thompson’s killing loom large at top health-care conference
82% Informative
JPMorgan 's annual health-care conference was held in San Francisco this week .
The conference took place a month after UnitedHealthcare CEO Brian Thompson was fatally shot in New York City .
Artificial intelligence, weight loss drugs and president-elect Donald Trump were popular topics of discussion.
Investors seem cautiously optimistic that the digital health market could turn a corner.
Some analysts estimate anti-obesity medications could grow into a $100 billion industry by the end of the decade .
Supply shortages are one of the big hurdles for companies in the market.
Many health-care executives are optimistic GLP-1s will meaningfully improve public health in the U.S ..